Drug Trial Radar · NCT06996119
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Nov 5, 2028
Study completion Nov 5, 2028
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.
Conditions
- Acute Myeloid Leukemia
- Graft Versus Host Disease
- Myelodysplastic Syndrome
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
BusulfanDrug
Given IV
Computed TomographyProcedure
Undergo chest CT
CyclophosphamideDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
EmapalumabBiological
Given IV
FludarabineDrug
Given IV
Hematopoietic Cell TransplantationProcedure
Given infusion
MelphalanDrug
Given IV
Multigated Acquisition ScanProcedure
Undergo MUGA
Mycophenolate MofetilDrug
Given IV or PO
Questionnaire AdministrationOther
Ancillary studies
TacrolimusDrug
Given IV or PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of grade 3 or higher adverse events (AEs)Time frame: From starting the first emapalumab dose to the first observation of a primary safety endpoint (PSE) event or day 28 post-hematopoietic cell transplantation (HCT), whichever comes first
- Incidence of severe infusion reactionTime frame: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first
- Incidence of primary graft failureTime frame: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first
- Non-relapse mortality (NRM)Time frame: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first
Locations
1 site in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.